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Fluoroquinolone Prophylaxis Against Febrile
Neutropenia in Areas With High Fluoroquinolone
Resistance—An Asian Perspective
Esther Shu-Ting Ng,1 Yixin Liew,2 Liang Piu Koh,3 Li Yang Hsu1*
Febrile neutropenia remains a major cause of morbidity and mortality in patients receiving chemotherapy.
Major prophylactic strategies include granulocyte colony-stimulating factor and antibiotics, the most
widely used of which are fluoroquinolones. While fluoroquinolone prophylaxis has been shown to be 
effective in areas where fluoroquinolone resistance is low, this same efficacy has not been proven in areas
where resistance is high, such as in Asia. Given the increase in antimicrobial resistance with the use of 
prophylaxis, the risks and benefits of this strategy need to be carefully considered. This review presents the
evidence for and against fluoroquinolone prophylaxis in areas of high fluoroquinolone resistance.
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Febrile neutropenia (FN) remains a major cause
of morbidity and mortality in patients receiving
chemotherapy. Given the risks and costs involved
in the treatment of FN, prophylactic approaches
directed against its development have gained
popularity and traction at many oncology and
hematology units worldwide. The two major pro-
phylactic strategies currently employed are the use
of granulocyte colony-stimulating factors (G-CSF)
and the use of antibiotics.
The use of G-CSF as primary prophylaxis to
reduce the risk of FN is well established. While it
has little measurable impact on overall survival,
it may reduce the risk of FN and early deaths, 
allowing for increased dose intensity of chemo-
therapy.1–4 The role of antibiotic prophylaxis has
been somewhat more controversial, particularly for
patients at low risk of FN. In the past, various types
of antibiotic prophylaxis against FN have been eval-
uated, including trimethoprim-sulfamethoxazole,
fluoroquinolones and various antibiotic combina-
tions (mainly fluoroquinolones in combination
with Gram-positive agents such as rifampicin, van-
comycin, amoxicillin or roxithromycin).5,6 How-
ever, fluoroquinolones have rapidly emerged as
the most commonly used prophylactic agents be-
cause of their broad antimicrobial spectrum, pre-
servation of anaerobic gut flora (with the exception
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of moxifloxacin), good oral bioavailability and
high therapeutic index.7
Benefits and Risks of Fluoroquinolone
Prophylaxis
Two recent large randomized controlled trials
demonstrated that fluoroquinolone prophylaxis
resulted in a lower incidence of FN episodes
post-chemotherapy in different patient popula-
tions.8,9 Bucaneve et al showed that levofloxacin
prophylaxis was effective in reducing FN inci-
dence in hospitalized patients receiving chemo-
therapy for lymphoma, leukemia and solid tumors
in an Italian center.8 Findings from Cullen et al
also corroborated this observation by demon-
strating decreased febrile episodes and hospital-
ization in an UK sample of outpatients given
chemotherapy for solid tumors or lymphomas.9
Both studies failed to show any overall survival
benefit for patients prescribed fluoroquinolones.
Meta-analyses, however, have tended to favor
fluoroquinolone prophylaxis as a strategy to de-
crease overall mortality post-chemotherapy. Based
on studies performed prior to 2003, Gafter-Gvili
et al showed that for patients with acute leukemia
who had undergone bone marrow transplanta-
tion, the relative risk (RR) of death with fluoro-
quinolone prophylaxis was 0.67 (95% confidence
interval = 0.55–0.83) in comparison to the con-
trol group.10 Among patients with solid tumors
and lymphomas, fluoroquinolone prophylaxis
had a significant impact on all-cause mortality
during the first cycle of chemotherapy, with a RR
of 0.48 (95% confidence interval = 0.26–0.88)
compared with controls.11 A later meta-analysis
incorporating only randomized placebo-controlled
trials showed a statistically non-significant, but
consistent, trend towards decreased mortality
when fluoroquinolone prophylaxis was employed
(RR = 0.76; 95% confidence interval: 0.54–1.08;
p = 0.13).12
However, the use of fluoroquinolone prophy-
laxis is not without risk. In neutropenic patients,
prior fluoroquinolone usage is a strong risk factor
for the development of fluoroquinolone-resistant
Escherichia coli bacteremia,13 which may be related
to the selection of pre-existing resistant mutants
of E. coli in the gastrointestinal tracts of these pa-
tients.14 In addition, an increased rate of fluoro-
quinolone-resistant streptococcal bacteremia has
been reported,15,16 likely arising from a higher
risk of oral colonization with fluoroquinolone-
resistant viridans streptococci.17
Nonetheless, Kern et al argued that fluoroqui-
nolone prophylaxis may still be beneficial despite
increased resistance.18 In a 6-month fluoroqui-
nolone prophylaxis discontinuation intervention
trial among acute leukemia patients, the investi-
gators found that the Gram-negative bacteremia
incidence rate increased to 20% from a low of
8% during the pre-intervention period. The re-
sumption of fluoroquinolone prophylaxis there-
after decreased the incidence of Gram-negative
bacteremia back to 9% while the proportion of
fluoroquinolone resistance in E. coli bacteremia
isolates again increased from 15% during the in-
tervention period to more than 50% in the post-
intervention period.18 The authors believed that the
relative proportion of resistance among E. coli did
not correlate with, and was not a good indicator
of, the protective efficacy of fluoroquinolone pro-
phylaxis. As with other studies, however, no statis-
tically significant impact on mortality was found
with regards to the initial rise and subsequent
decline of Gram-negative bacteremia rates.18
Geographic Fluoroquinolone Resistance
is Higher in Asian Countries
Several surveillance studies in varied clinical set-
tings suggest that fluoroquinolone resistance is
widespread in most parts of Asia. In the 2004
Study for Monitoring Antimicrobial Resistance
Trends, which included worldwide data on Gram-
negative bacilli that caused intra-abdominal infec-
tions, the highest rate of fluoroquinolone resistance
was found in the Asia-Pacific region.19 In China,
53–57% of clinical strains of E. coli were resistant
to ciprofloxacin.20 In a Korean study on outpatient
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urinary tract infections, ciprofloxacin resistance
rates were 43.4% in E. coli, 43.9% in Klebsiella
pneumoniae and 86.8% in Pseudomonas aeruginosa.21
In Singapore, a hospital-based surveillance pro-
gram showed that 34.4% and 42.5% of clinical
E. coli and K. pneumoniae isolates, respectively, were
resistant to ciprofloxacin.22
In comparison, the European Antimicrobial
Resistance Surveillance System23 reported that 
in 2007, only 19.7% and 19.0% of bloodstream 
E. coli and K. pneumoniae isolates in Europe were
resistant to fluoroquinolones. In North America,
the data have been variable but resistance rates are
generally lower than those reported in Asia. As
an example, Zhanel et al studied urinary tract
pathogens among outpatients with urinary tract
infection. Among all isolates, 9.7% were resistant
to ciprofloxacin, whereas only 5.5% of E. coli iso-
lates were resistant to ciprofloxacin.24
We conducted a PubMed search specific to adult
patients with febrile neutropenia in Asia, using
the following keywords in combination: “Asia”,
“Korea”, “China”, “quinolones”, “fluoroquinolo-
nes”, “ciprofloxacin”, “levofloxacin”, “antibiotics”
and “febrile neutropenia”. English language articles
and foreign language articles with English trans-
lation were included in our review. Data on an-
timicrobial use and antimicrobial resistance were
collected. The results of representative studies are
shown in the Table.25–33
Unlike European and US reports, where the
majority of bacteremias in patients with FN are
due to Gram-positive bacteria,34,35 the majority of
Asian reports demonstrate overall predominance
of Gram-negative bacilli, in particular Entero-
bacteriaceae.25–33 The reason for this discrepancy
is unclear, as it is likely that the use of central
catheters, fluoroquinolone prophylaxis and ag-
gressive chemotherapy with significant mucositis—
touted as the reasons for the predominance of
Gram-positive organisms in FN—are just as wide-
spread in Asian centers as in Western centers.
Fluoroquinolone resistance was high among
the Gram-negative bacteria cultured in the Asian
studies, ranging up to 80% of all isolates. Chen
et al reported 33% of E. coli isolates as resistant
to fluoroquinolones, even though no fluoroqui-
nolone prophylaxis was used.28 With such high
baseline rates of resistance, it is conceivable that
fluoroquinolone prophylaxis would not only be
ineffective in preventing FN in post-chemotherapy
patients from Asian countries, but could further
augment the resistance rates. The above observa-
tions imply a decreased applicability of findings
from Western studies and meta-analyses, such as
Kern et al,18 to an Asian context, where the fluo-
roquinolone resistance rates are generally higher
compared to European and US populations.
Current Recommendations on
Fluoroquinolone Prophylaxis
In 2008, the US National Comprehensive Cancer
Network published guidelines on the preven-
tion and treatment of cancer-related infections.
Prophylactic fluoroquinolones were recommended
for high-risk and intermediate-risk groups, com-
prising patients receiving high-dose chemother-
apy and those in whom the anticipated duration
of neutropenia is longer than 7 days.1 Cullen and
Baijal further recommended that patients with
solid malignancies undergoing standard outpa-
tient cyclical chemotherapy should also receive
fluoroquinolone prophylaxis especially in the
first cycle, if grade 4 neutropenia is expected, i.e.
regimens containing docetaxel, doxorubicin or
vinorelbine.36 However, concerns had previously
been raised about whether the selection of fluo-
roquinolone-resistant flora during the first cycle
of chemotherapy would increase the incidence
of resistant Gram-negative organisms in subse-
quent courses.37
Efficacy and Impact of Fluoroquinolone
Prophylaxis in Institutions With High
Pre-existing Gram-negative
Fluoroquinolone Resistance
A Mexican study on the use of ciprofloxacin among
patients with acute leukemia found that bacteremia
Fluoroquinolone prophylaxis—an Asian perspective
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was similar between the prophylaxis and control
group.38 In that population, the prevalence of
ciprofloxacin resistance was relatively high; 24%
of adults and 26% of children who visited the
emergency room with no known exposure to flu-
oroquinolones in the preceding 3 months har-
bored ciprofloxacin-resistant E. coli in their feces.
Gomez et al found that there was a trend towards
a higher rate of Gram-positive bacteremia in the
control group and a higher rate of Gram-negative
bacteremia in the ciprofloxacin group. Resistance
to fluoroquinolones was greater in E. coli blood
isolates from patients in the ciprofloxacin group.38
The evidence thus far is mixed with regards 
to the question of whether fluoroquinolone pro-
phylaxis is efficacious in preventing FN in patients
who have documented infection or colonization
with fluoroquinolone-resistant organisms.18,37
Patients who are colonized by fluoroquinolone-
resistant bacteria are more likely to have previous
exposure to antibiotics. These may also be patients
with previous episodes of FN. As previous FN is
an independent predictor for further FN,39 high-
risk patients might be deprived of effective pro-
phylaxis if fluoroquinolones are withheld. After
all, colonization with resistant Gram-negative bac-
teria might well be transitory. In a study conducted
by Perea et al, 10 out of 21 patients were colo-
nized by fluoroquinolone-resistant E. coli after 
8 days of prophylaxis. There were no differences
in infectious complications in patients colonized
with resistant flora. After discontinuation of pro-
phylaxis, only two out of the 10 patients remained
colonized, hence previous documentation of col-
onization or infection with resistant flora does not
reliably predict that fluoroquinolone prophylaxis
would be ineffective.37
However, the use of fluoroquinolones has also
been associated with the emergence of other antibi-
otic-resistant pathogens, including carbapenem-
resistant organisms.40,41 In patients at high risk of
FN who are already colonized with fluoroquino-
lone-resistant organisms, the further use of fluo-
roquinolones may not prevent FN, but may instead
lead to the development of carbapenem or other
antibiotic resistance.
Role of Further Studies on
Fluoroquinolone Prophylaxis in Regions
With High Existing Fluoroquinolone
Resistance
Are further studies regarding fluoroquinolone
prophylaxis necessary? Kern et al documented
the effectiveness of fluoroquinolone prophylaxis
despite its effect on increasing resistance rates.
However, this study used a German sample,
where baseline resistance rates were low.18 An-
other study (from a hospital in Barcelona) also
showed that the discontinuation of norfloxacin
prophylaxis led to a rapid increase in the rate of
fluoroquinolone-susceptible enterobacterial in-
fections; however, there was little impact on in-
fectious morbidity.42
Studies in Asian populations with high popu-
lation resistance rates are necessary as results may
differ significantly from those described by Kern
et al. Such studies would not be without risk. First,
the discontinuation of prophylaxis in high-risk
patients may result in an increase in FN episodes.
Second, the discontinuation and reinitiation of
antibiotics may add to resistance selection pressure.
Where baseline fluoroquinolone resistance is
high and fluoroquinolone prophylaxis may be
less effective, alternative strategies of prophylaxis
should be considered.
Current guidelines recommend that patients
whose risk of FN is 20% or greater should be given
primary prophylactic G-CSF.43 A large study has
shown that the addition of G-CSF to prophylactic
antibiotics led to a further decrease in the incidence
of FN.38 In this study, the antibiotic prophylaxis
used was a combination of ciprofloxacin and rox-
ithromycin.38 In areas of high fluoroquinolone
resistance, where fluoroquinolone prophylaxis may
be less effective, we suggest lowering the threshold
for G-CSF prophylaxis, especially in patients with
documented previous infection or colonization
with fluoroquinolone resistant organisms.
However, the use of G-CSF is not without po-
tential risk in certain clinical situations. There is
a small theoretical risk of stimulating underlying
disease during allogeneic stem cell transplantation
Fluoroquinolone prophylaxis—an Asian perspective
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of patients with monosomy 7 acute myeloid leu-
kemia.44 No conclusive benefit in terms of survival
has been documented with regards to its use in leu-
kemia or allogeneic stem cell transplantation.44
We need better models of neutropenia risk that
incorporate both G-CSF and fluoroquinolone pro-
phylaxis that take into account the population
baseline resistance rates.
Conclusions
FN is a major cause of mortality and morbidity
in cancer patients worldwide. Antibiotic prophy-
laxis, most commonly with fluoroquinolones,
has been shown to be effective in preventing FN
within areas with low prevalence of fluoroqui-
nolone resistance, but this may not hold true in
areas of high prevalence.
The prevalence of fluoroquinolone resistance
is higher in Asia compared with the United States
and Europe, and further studies are required to
evaluate the efficacy of fluoroquinolone prophy-
laxis in Asia. This is due to the view that the use
of prophylaxis has been proven to cause an in-
crease in fluoroquinolone-resistant organisms.
Better models of neutropenia risk are needed,
which incorporate both G-CSF and antibiotic
prophylaxis. These models should include indi-
vidualized calculation of FN risk, so as to permit
the identification of high-risk patients who may
benefit from fluoroquinolone prophylaxis while
minimizing antibiotic selection pressure from
less discriminate prescription of these antibiotics.
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